Overview
- Bagnis entered a voluntary provisional suspension on October 18 under the Tennis Anti-Doping Programme, which will count as time served toward any future sanction.
- An in-competition A sample collected on August 18 during US Open qualifying tested positive for hydrochlorothiazide, a WADA-listed diuretic classified as a specified substance.
- The ITIA issued a pre-charge notice on October 2, and Bagnis did not hold a Therapeutic Use Exemption for the substance.
- While suspended, he is barred from competing in, coaching at, or attending events sanctioned by the ATP, WTA, ITF, and Grand Slam bodies.
- Bagnis denies intentional use, is cooperating with investigators, and has engaged legal and medical experts to examine potential cross-contamination as the case moves toward B-sample confirmation and a hearing.